Mark Turco Named CEO at Field Medical

Field Medical Inc. has chosen a new leader. Mark A. Turco, M.D., now occupies the corner office, drawing on his more than 30 years of leadership experience spanning venture-backed cardiovascular startups and executive roles within large-cap medical device organizations.

Dr. Turco has led multiple clinical-stage companies through development and strategic transactions, building organizations positioned for long-term scale.

“Mark’s unique background as a cardiologist, clinical trialist, and an experienced medical device executive equips him well to guide Field Medical through this next phase of growth,” said Ben Cannon, a Field Medical board member and constituent of the BioStar Capital and Cue Growth investment teams. “As we accelerate our clinical programs and strengthen our operational capabilities, his executive experience in advancing complex medical technologies across development, regulatory, and commercialization milestones will enable disciplined execution and sustainable long-term value creation.”

Dr. Turco was president and CEO of JC Medical Inc., where he led development of a dedicated transcatheter aortic valve replacement (TAVR) system for aortic regurgitation; the company was acquired in July 2024 by Edwards Lifesciences. Before that, he held senior leadership roles at Medtronic and Covidien, serving as vice president and chief medical officer of the vascular and neurovascular franchises, and most recently served as president and CEO of the Rhode Island Life Science Hub. A board-certified interventional cardiologist before transitioning to industry, Dr. Turco brings both clinical insight and operational experience to Field Medical’s leadership team.

“I am honored to join Field Medical at this pivotal moment in its evolution,” Dr. Turco stated. “The company has built a differentiated PFA platform with the potential to meaningfully address significant unmet patient needs in both ventricular arrhythmias and atrial fibrillation. I look forward to partnering closely with the exceptional Field Medical team to advance our clinical programs and navigate regulatory pathways to meet our operational goals.”

Founded in 2022, Field Medical is a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System integrates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient, precise ablation to improve outcomes in ventricular and atrial arrhythmia treatment. In 2024, Field Medical earned U.S. Food and Drug Administration (FDA) Breakthrough Device Designation and gained entry into the FDA TAP Pilot Program for its ventricular tachycardia indication. In October 2025, the VCAS trial was published in Circulation.

The FieldForce Ablation System is an investigational device and is limited by U.S. law to investigational use.